Does Dr. ABDEL ABU SHAMAT have financial conflicts of interest?

Dr. ABDEL ABU SHAMAT (MD) has received a total of $4,410 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $4,410 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ABDEL ABU SHAMAT?

According to CMS Open Payments data, Dr. ABDEL ABU SHAMAT received funding from ASTRAZENECA PHARMACEUTICALS ($633), AKEBIA THERAPEUTICS ($469), and AMGEN ($439).

Does Dr. ABDEL ABU SHAMAT receive research grants or speaking fees?

Dr. ABDEL ABU SHAMAT has received $4,410 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. ABDEL ABU SHAMAT

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: LAKE CHARLES, LA 70601

NPI Number: 1528053824

LIFETIME INDUSTRY VALUE

$4,410

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABU SHAMAT is a verified Internal Medicine, Nephrology practitioner based in LAKE CHARLES, LA.

Between 2021 and 2024, Dr. ABU SHAMAT had an overall industry promotional and research financial footprint of $4,410 as recorded in the federal CMS Open Payments database.

$4,410 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABU SHAMAT's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $633 (representing 14.4% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$633

14.4%

AKEBIA THERAPEUTICS

Rank 2

$469

10.6%

AMGEN

Rank 3

$439

9.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.